BSE filing, NSE: BIJHANS. Summary written from the filing by ALFA Finder's alert engine.
Arvaya Healthcare Ltd: key numbers
- Share price
- ₹108.95
- Market cap
- ₹523.2 Cr
- Revenue (annual)
- ₹9.11 Cr
- Net profit (annual)
- ₹0.70 Cr
- P/E (TTM)
- 339.4×Sector 36.4×
- Promoter holding
- 30.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Arvaya Healthcare Ltd
All →Arvaya Healthcare Preferential Issue
Director Bidari Kotresh Anilkumar acquired 591,129 Arvaya Healthcare shares through a preferential offer. Holding rises to 4.45% from 3.58%.
Arvaya Healthcare Preferential Issue
Arvaya Healthcare allotted 38,71,854 equity shares at Rs.40 each to 47 SIGPL shareholders in a share swap. The allotment is valued at Rs.15.49 Crore.
- Value
- ₹15.49 Cr
Arvaya Healthcare Board Meeting Date
Arvaya Healthcare will hold a board meeting on October 24, 2026, to consider a preferential allotment of 38.72 lakh equity shares to SIGPL shareholders.
Arvaya Healthcare Preferential Issue
Arvaya Healthcare received BSE in-principle approval to issue 38,71,854 equity shares at Rs. 40 each. This preferential allotment totals Rs. 15.49 Crore.
- Value
- ₹15.49 Cr
Arvaya Healthcare Annual General Meeting
Arvaya Healthcare Limited held its 41st Annual General Meeting on 21st September 2026, where members adopted financial statements and approved material related party transactions.
Arvaya Healthcare Merger & Restructuring Worth ₹0.8 Cr
Arvaya Healthcare has incorporated a wholly-owned subsidiary, Arvaya Insurance Broking Private Limited, for an investment of ₹0.80 Crore. This entity will provide insurance broking services.
- Value
- ₹0.80 Cr
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.